✔ COMPLIANT
★★☆
Pharmaceuticals | USA
Business: PASS
BioDelivery Sciences International Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
Financials: PASS
The financials pass two standards and fail in one.
FTSE
| Debt/A | 32.7% | ✔ |
| Cash/A | 46.51% | ✘ |
| (AR+C)/A | 46.51% | ✔ |
AAOIFI
| Debt/MC | 14.28% | ✔ |
| Cash/MC | % |
DJIM
| Debt/24MC | 20.36% | ✔ |
| Cash/24MC | 28.96% | ✔ |
| AR/24MC | % |
Total Analysts: 7
Recommendation Rating
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Low: 7
High: 8
| Market cap | 549305421 |
| Assets | 239894000 |
| Dividends per Share | |
| Revenue Growth | 40.5 |
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
| ✘ FTSE | ✔ AAOIFI | ✔ DJIM |
✔ COMPLIANT
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses